Saxagliptin is a new oral hypoglycemic of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus.

709031-78-7

C18H26ClN3O2

351.87

Saxagliptin;BMS 477118;BMS477118;BMS-477118;Saxagliptin HCl;Saxagliptin hydrochloride

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years